Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.50
ISIS's Cash to Debt is ranked lower than
75% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. ISIS: 1.50 )
Ranked among companies with meaningful Cash to Debt only.
ISIS' s 10-Year Cash to Debt Range
Min: 0.24  Med: 1.41 Max: 4.87
Current: 1.5
0.24
4.87
Equity to Asset 0.29
ISIS's Equity to Asset is ranked lower than
85% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ISIS: 0.29 )
Ranked among companies with meaningful Equity to Asset only.
ISIS' s 10-Year Equity to Asset Range
Min: -0.85  Med: 0.33 Max: 0.76
Current: 0.29
-0.85
0.76
F-Score: 4
Z-Score: 5.33
M-Score: -1.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -11.02
ISIS's Operating margin (%) is ranked higher than
63% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. ISIS: -11.02 )
Ranked among companies with meaningful Operating margin (%) only.
ISIS' s 10-Year Operating margin (%) Range
Min: -438.91  Med: -80.37 Max: -12.18
Current: -11.02
-438.91
-12.18
Net-margin (%) -9.82
ISIS's Net-margin (%) is ranked higher than
62% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. ISIS: -9.82 )
Ranked among companies with meaningful Net-margin (%) only.
ISIS' s 10-Year Net-margin (%) Range
Min: -334.33  Med: -102.40 Max: 127.52
Current: -9.82
-334.33
127.52
ROE (%) -7.54
ISIS's ROE (%) is ranked higher than
67% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. ISIS: -7.54 )
Ranked among companies with meaningful ROE (%) only.
ISIS' s 10-Year ROE (%) Range
Min: -280.13  Med: -40.12 Max: 86.43
Current: -7.54
-280.13
86.43
ROA (%) -2.80
ISIS's ROA (%) is ranked higher than
71% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. ISIS: -2.80 )
Ranked among companies with meaningful ROA (%) only.
ISIS' s 10-Year ROA (%) Range
Min: -59.44  Med: -21.74 Max: 25.19
Current: -2.8
-59.44
25.19
ROC (Joel Greenblatt) (%) -12.06
ISIS's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. ISIS: -12.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ISIS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -800.86  Med: -124.62 Max: -22.1
Current: -12.06
-800.86
-22.1
Revenue Growth (3Y)(%) 22.50
ISIS's Revenue Growth (3Y)(%) is ranked higher than
79% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ISIS: 22.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ISIS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -39.4  Med: -2.30 Max: 83.7
Current: 22.5
-39.4
83.7
EBITDA Growth (3Y)(%) -30.30
ISIS's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. ISIS: -30.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ISIS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -49.6  Med: -4.50 Max: 61.3
Current: -30.3
-49.6
61.3
EPS Growth (3Y)(%) -27.00
ISIS's EPS Growth (3Y)(%) is ranked lower than
74% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ISIS: -27.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ISIS' s 10-Year EPS Growth (3Y)(%) Range
Min: -71.2  Med: 2.00 Max: 117.8
Current: -27
-71.2
117.8
» ISIS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ISIS Guru Trades in Q2 2014

Murray Stahl 17,000 sh (unchged)
Jim Simons Sold Out
Ron Baron Sold Out
George Soros Sold Out
» More
Q3 2014

ISIS Guru Trades in Q3 2014

Murray Stahl 17,000 sh (unchged)
» More
Q4 2014

ISIS Guru Trades in Q4 2014

Paul Tudor Jones 6,473 sh (New)
Joel Greenblatt 8,745 sh (New)
Murray Stahl 17,000 sh (unchged)
» More
Q1 2015

ISIS Guru Trades in Q1 2015

Murray Stahl 17,000 sh (unchged)
Paul Tudor Jones 6,390 sh (-1.28%)
Joel Greenblatt 7,892 sh (-9.75%)
» More
» Details

Insider Trades

Latest Guru Trades with ISIS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 23.39
ISIS's P/B is ranked lower than
93% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ISIS: 23.39 )
Ranked among companies with meaningful P/B only.
ISIS' s 10-Year P/B Range
Min: 3  Med: 10.06 Max: 1710
Current: 23.39
3
1710
P/S 25.61
ISIS's P/S is ranked lower than
69% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. ISIS: 25.61 )
Ranked among companies with meaningful P/S only.
ISIS' s 10-Year P/S Range
Min: 4.33  Med: 12.80 Max: 84.47
Current: 25.61
4.33
84.47
EV-to-EBIT -517.33
ISIS's EV-to-EBIT is ranked lower than
473% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. ISIS: -517.33 )
Ranked among companies with meaningful EV-to-EBIT only.
ISIS' s 10-Year EV-to-EBIT Range
Min: -311.1  Med: -14.70 Max: 596.9
Current: -517.33
-311.1
596.9
Current Ratio 8.33
ISIS's Current Ratio is ranked higher than
69% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ISIS: 8.33 )
Ranked among companies with meaningful Current Ratio only.
ISIS' s 10-Year Current Ratio Range
Min: 2.49  Med: 4.73 Max: 9.89
Current: 8.33
2.49
9.89
Quick Ratio 8.26
ISIS's Quick Ratio is ranked higher than
69% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. ISIS: 8.26 )
Ranked among companies with meaningful Quick Ratio only.
ISIS' s 10-Year Quick Ratio Range
Min: 2.49  Med: 4.68 Max: 9.89
Current: 8.26
2.49
9.89
Days Sales Outstanding 39.55
ISIS's Days Sales Outstanding is ranked higher than
70% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. ISIS: 39.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISIS' s 10-Year Days Sales Outstanding Range
Min: 1.87  Med: 32.71 Max: 86.04
Current: 39.55
1.87
86.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 415.08
ISIS's Price/Net Cash is ranked lower than
98% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. ISIS: 415.08 )
Ranked among companies with meaningful Price/Net Cash only.
ISIS' s 10-Year Price/Net Cash Range
Min: 4.75  Med: 22.89 Max: 489.77
Current: 415.08
4.75
489.77
Price/Net Current Asset Value 41.51
ISIS's Price/Net Current Asset Value is ranked lower than
92% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. ISIS: 41.51 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ISIS' s 10-Year Price/Net Current Asset Value Range
Min: 4.49  Med: 15.34 Max: 705.5
Current: 41.51
4.49
705.5
Price/Tangible Book 25.21
ISIS's Price/Tangible Book is ranked lower than
91% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. ISIS: 25.21 )
Ranked among companies with meaningful Price/Tangible Book only.
ISIS' s 10-Year Price/Tangible Book Range
Min: 2.82  Med: 8.97 Max: 216.67
Current: 25.21
2.82
216.67
Price/Median PS Value 2.00
ISIS's Price/Median PS Value is ranked lower than
76% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. ISIS: 2.00 )
Ranked among companies with meaningful Price/Median PS Value only.
ISIS' s 10-Year Price/Median PS Value Range
Min: 0.2  Med: 0.93 Max: 5.04
Current: 2
0.2
5.04
Earnings Yield (Greenblatt) (%) -0.20
ISIS's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ISIS: -0.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ISIS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -0.2  Med: 0.20 Max: 0.3
Current: -0.2
-0.2
0.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ISIS.Switzerland, 0R0N.UK, ISI.Germany,
Isis Pharmaceuticals Inc was incorporated in California in 1989, and in January 1991 the Company changed its state of incorporation to Delaware. The Company is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a pipeline of first-in-class drugs. Antisense technology provides a direct route from genomics to drugs. The Company business segments are Drug Discovery and Development operations. Its flagship product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia, or HoFH. Patients with HoFH are at high cardiovascular risk and cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies. The Company has a pipeline of 31 drugs in development. Company's ISIS-TTR and ISIS-SMN drugs are in late stage development. Its partners include Biogen Idec, AstraZeneca and Roche. The Company's drugs compete with existing therapies for market share. It also competes with specialized pharmaceutical firms and large pharmaceutical companies acting either independently or together with biopharmaceutical companies. The Company is subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state and local regulations.
» More Articles for ISIS

Headlines

Articles On GuruFocus.com
buffet May 31 2015 
buffet May 31 2015 
Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
Analysts Provide Update for Biogen, PTC Therapeutics, GW Pharma, and Isis Pharma Apr 22 2015 
Value vs. Growth: Is Jim Cramer Right about ISIS Pharmaceuticals? Dec 13 2014 
Weekly CEO Sells Highlight: Keynote Systems Inc., Isis Pharmaceuticals, Coleman Cable Inc. Jul 01 2013 
Isis Pharmaceuticals Inc. (ISIS) Director, COO B Lynne Parshall sells 17,200 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. (ISIS) Chairman, President, CEO Stanley T Crooke sells 32,000 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients... Aug 03 2015
Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients... Aug 03 2015
Will Isis Pharmaceuticals (ISIS) Beat Q2 Earnings Estimates? - Analyst Blog Aug 03 2015
Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop... Aug 03 2015
ISIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Aug 03 2015
5:42 am ISIS Pharm and AstraZeneca (AZN) enter into strategic... Aug 03 2015
AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular,... Aug 03 2015
Astrazeneca Expands Work With Isis to Use Genes to Fix Diseases Aug 03 2015
AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular,... Aug 03 2015
AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular,... Aug 03 2015
Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine Jul 29 2015
Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine Jul 29 2015
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call Jul 28 2015
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call Jul 28 2015
Lightning Round: $43 oil is a perfect price for it Jul 27 2015
ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related... Jul 27 2015
ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related... Jul 27 2015
Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet Jul 22 2015
Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet Jul 22 2015
Isis Pharmaceuticals Begins Huntington's Disease Study - Analyst Blog Jul 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK